ArriVent BioPharma announces 2026 annual meeting voting results; directors elected, auditor ratified

ArriVent BioPharma, Inc.

Stockholders elected James Healy, John Hohneker, and Stuart Lutzker as Class II directors for three-year terms.
Healy received 18,058,285 votes for; Hohneker 28,043,164; Lutzker 29,495,923; broker non-votes 3,832,858 each.
Ratification of PricewaterhouseCoopers LLP as auditor for FY 2026 passed with 33,411,773 votes for, 829 against.
Quorum of 33,418,793 shares (72.07% of eligible) was present at the meeting.

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ArriVent BioPharma, Inc. shareholders approved Election of Directors at the 2026-06-18 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-18

Exact text from the filing

1. Election of Directors Nominee Shares Voted For Shares Voted to Withhold Authority Broker Non-votes James Healy, M.D., Ph.D. 18,058,285 11,527,650 3,832,858 John Hohneker, M.D. 28,043,164 1,542,771 3,832,858 Stuart Lutzker, M.D., Ph.D. 29,495,923 90,012 3,832,858

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ArriVent BioPharma, Inc. shareholders approved Auditor Ratification at the 2026-06-18 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-18

Exact text from the filing

2. Auditor Ratification Shares Voted For Shares Voted Against Shares Abstaining Broker Non-votes 33,411,773 829 6,191 0

View on SEC.gov

Browse all shareholder votes →

ArriVent BioPharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-076352

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.